NEW TEST

Click for Pricing

Envoplakin Antibody, IgG by ELISA

3016533, ENVO IGG

Specimen Requirements:	
Patient Preparation:	
Collect:	Plain red or serum separator tube (SST).
Specimen Preparation:	Transfer 2 mL serum to an ARUP standard transport tube. (Min: 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Hemolyzed or lipemic specimens. Plasma
Remarks:	
Stability:	Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely
Methodology:	Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Performed:	Varies
Reported:	7-14 days
Note:	The methodology is enzyme-linked immunosorbent assay (ELISA) to detect IgG antibodies to envoplakin. This test should be distinguished from antibody testing of cerebral spinal fluid (CSF) for paraneoplastic neurologic syndromes; 3004510, 3004512, 3004517 are different tests. Paraneoplastic pemphigus (PNP), also known as paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare paraneoplastic disease that affects patients of all ages, is associated with lymphoproliferative disorders/malignancies and demonstrates clinical features of severe pemphigus with a high mortality rate. Patients with PNP/PAMS develop serum antibodies to multiple epithelia (simple, columnar, transitional) with several possible epithelial antigen targets. Envoplakin is one of several possible epithelial targets, albeit a major one. The IgG envoplakin antibody level by ELISA, increased or normal (positive or negative), as a stand-alone diagnostic test, does not completely confirm or rule out a diagnosis of PNP/PAMS; its usefulness is as a marker in conjunction with other indicators. Additionally, IgG envoplakin antibody levels, when increased, may correlate with disease extent and activity

	and, therefore, can be useful in disease monitoring.
CPT Codes:	83516
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data: Refer to report.	
Reference Interval:	

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.